European Medicines Agency (EMA) announces termination of Avandia (rosiglitazone usage in Europe)
Во время 46 конгресса Европейской ассоциации по изучению диабета (EASD), проходившего в г. Стокгольме 23 сентября, Европейское медицинское агентство (EMA) заявило о приостановлении на ближайшие несколько месяцев разрешения на распространение в Европе розиглитазон-содержащих препаратов, таких как Ава...
Main Author: | Inna Igorevna Klefortova |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2010-09-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://dia-endojournals.ru/dia/article/viewFile/5509/3307 |
Similar Items
-
Effects of Rosiglitazone on Nitrolgycerin-induced Endothelial Dysfunction
by: Perampaladas, Kumar
Published: (2010) -
Effects of Rosiglitazone on Nitrolgycerin-induced Endothelial Dysfunction
by: Perampaladas, Kumar
Published: (2010) -
The Europeanization of Public Administration through the General Principles of Good Administration
by: Vasilica NEGRUŢ
Published: (2011-08-01) -
Effect of Rosiglitazone on Coronary Angiogenesis in Diabetic and Control Rats
by: Ensieh Salehi, et al.
Published: (2011-06-01) -
Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice
by: Laale F. Alawi, et al.
Published: (2020-02-01)